An update on amebiasis;Amebiasis: Aspectos clínicos, terap

Revista Medica de Chile

Volumn 141, Issue 5, 2013, Pages 609-615

  Chacín Bonilla, Leonor ^a  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Amebiasis; Diagnosis; Entamoeba histolytica; Epidemiology; Treatment

Indexed keywords

PROTOZOAL DNA;

AMEBIASIS; ENTAMOEBA HISTOLYTICA; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; GENETICS; HOST PARASITE INTERACTION; HUMAN; PARASITOLOGY; PATHOGENICITY; POLYMERASE CHAIN REACTION; REVIEW;

AMEBIASIS; DNA, PROTOZOAN; ENTAMOEBA HISTOLYTICA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; HOST-PARASITE INTERACTIONS; HUMANS; POLYMERASE CHAIN REACTION;

EID: 84883151843     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872013000500009     Document Type: Review

References (49)

1. WHO/PAHO/UNESCO. A consultation with experts on amoebiasis. Epidemiol Bull 1997; 18 (1): 13-4.
2. Walsh JA. Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Rev Infect Dis 1986; 8: 228-38.
3. Chacín-Bonilla L. Amibiasis: Implicaciones del reconocimiento de Entamoeba dispar e identificación de Entamoeba moshkovskii en humanos. Invest Clin 2010; 51 (2): 239-56.
4. Costa CA, Brito KN, Gómes MA, Caliari MV. Histopathological and immunohistochemical study of the hepatic lesions experimentally induced by Entamoeba dispar. Eur J Histochem 2010; 54 (e39): 170-4.
5. Jackson TF. Entamoeba histolytica and Entamoeba dispar are distinct species; clinical, epidemiological and serological evidence. Int J Parasitol 1998; 28: 181-6.
6. Rivera WL, Tachibana H, Kanbara H. Field study on the distribution of Entamoeba histolytica Entamoeba dispar in the Northern Philippines as detected by the polimerase chain reaction. Am J Trop Med Hyg 1998; 59 (6): 916-21.
7. Braga LL, Mendonca Y, Paiva CA, Sales A, Cavalcante AL, Mann BJ. Seropositivity for and intestinal colonization with Entamoeba histolytica and Entamoeba dispar in individuals in Northeastern Brazil. J Clin Microbiol 1998; 36 (10): 3044-5.
8. Ramos F, Morán P, González E, García G, Ramiro M, Gómez A, et al. High prevalence rate of Entamoeba histolytica asymptomatic infection in a rural Mexican community. Am J Trop Med Hyg 2005; 73 (1): 87-91.
9. Leiva B, Lebbad M, Winiecka-Krusnell J, Altamirano I, Téllez A, Linder E. Overdiagnosis of Entamoeba histolytica and Entamoeba dispar in Nicaragua. A microscopic, triage parasite panel and PCR study. Arch Med Res 2006; 37 (4): 529-34.
10. Levecke B, Dreesen L, Barrionuevo-Samaniego M, Benítez Ortíz W, Praet N, Brandt J et al. Molecular differentiation of Entamoeba spp. in a rural community of Loja province, South Ecuador. Trans R Soc Trop Med Hyg 2011; 105: 737-9.
11. Haque R, Mondal D, Duggal P, Kabir M, Roy S, Far BM et al. Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun 2006; 74 (2): 904-9.
12. Tanyuksel M, Petri WA Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev 2003; 16 (4): 713-9.
13. Caballero-Salcedo A, Viveros-Rogel M, Salvatierra B, Tapia-Conyer R, Sepúlveda-Amor J, Gutiérrez G. Seroepidemiology of amebiasis in México. Am J Trop Med Hyg 1994; 50 (4): 412-9.
14. Braga LL, Lima AM, Sears CL, Newman RD, Wuhib T, Paiva CA, et al. Seroepidemiology of Entamoeba histolytica in a slum in northeastern Brazil. Am J Trop Med Hyg 1996; 55 (6): 693-7.
15. Chacín-Bonilla L, Bonpart D. A seroepidemiological study of amebiasis in adults in Venezuela. Am J Trop Med Hyg 1981; 30 (6): 1201-5.
16. Chacín-Bonilla L, Chacín-Martínez E, Espinoza E, Cárdenas B. A seroepidemiological study of amebiasis in children of low socioeconomic level in Maracaibo, Venezuela. Am J Trop Med Hyg 1982; 31 (6): 1103-6.
17. Chacín-Bonilla L, Mathews HM, Gealy GR, Dikdan Y, Rodríguez-Zambrano N. Serologic and parasitological studies of amebiasis in two suburban communities of Maracaibo, Venezuela. Invest Clin 1984; 25 (2): 69-80.
18. Chacín-Bonilla L, Mathews HM, Dikdan Y, Guanipa N. Estudio seroepidemiológico de la amibiasis en una comunidad del estado Zulia, Venezuela. Rev Inst Med Trop Sao Paulo 1990; 32 (6): 467-3.
19. Petri WA Jr, Mondal D, Peterson KM, Duggal P, Haque R. Association of malnutrition with amebiasis. Nutr Rev 2009; 67 (Suppl. 2): S207-15.
20. Stauffer W, Abd-Alla M, Ravdin JI. Prevalence and incidence of Entamoeba histolytica infection in South Africa and Egypt. Arch Med Res 2006; 37: 266-9.
21. Hung CC, Deng HY, Hsiao WH, Hsieh SM, Hsiao CF, Chen MY, et al. Invasive amoebiasis as an emerging parasitic disease in patients with human immunodeficiency virus type-1 infection in Taiwan. Arch Inter Med 2005; 165: 409-5.
22. Morán P, Gómez A, Valadez A, García G, Ramos F, González E, et al. Periodicity and patterns of Entamoeba histolytica and Entamoeba dispar infection in HIV+/AIDS patients in Mexico. Ann Trop Med Parasitol 2009; 103 (4): 307-15.
23. Haghihgi A, Kobayashi S, Takeuchi T, Thammapalerd N, Nozaki T. Geographic diversity among genotypes of Entamoeba histolytica field isolates. J Clin Microbiol 2003; 4: 3748-56.
24. Beaver PC, Jung RC, Cupp EW. Parasitología Clínica. Editores Salvat, Barcelona, España. 1986; 882 pp.
25. Schuster FL, Visvesvara GS. Amebae and ciliated protozoa as causal agents of waterborne zoonotic disease. Vet Parasitol 2004; 126: 91-120.
26. Thompson RCA. The zoonotic significance and molecular epidemiology of Giardia and giardiasis. Vet Parasitol 2004; 126: 15-35.
27. Gathiram V, Jackson TF. A longitudinal study of asymptomatic carriers of pathogenic zimodemes of Entamoeba histolytica. S Afr Med J 1987; 72 (10): 669-72.
28. Mondal D, Petri WA Jr, Sack RB, Kirkpatrick BD, Haque R. Entamoeba histolytica-associated diarrheal illness is negatively associated with the growth of preschool children: evidence from a prospective study. Trans R Soc Trop Med Hyg 2006; 100: 1032-8.
29. Ralston KS, Petri WA Jr. Tissue destruction and invasion by Entamoeba histolytica. Trends Parasitol 2011; 27 (6): 253-62.
30. Duggal P, Guo X, Haque R, Peterson KM, Ricklefs S, Mondal D. A mutation in the leptin receptor is associated with Entamoeba histolytica infection in children. J Clin Invest 2011; 121: 1191-8.
31. Lotter H, Jacobs T, Gaworski I, Tannich E. Sexual dimorphism in the control of amebic liver abscess in a mouse model of disease. Infect Immun 2006; 74: 118-24.
32. Snow M, Chen M, Guo J, Atkinson J, Stanley SL Jr. Differences in complement-mediated killing of Entamoeba histolytica between men and women-an explanation for the increased susceptibility of men to invasive amebiasis? Am J Trop Med Hyg 2008; 78 (6): 922-3.
33. Ali IK, Solaymani-Mohammadi S, Akhter J, Roy S, Gorrini C, Calderaro A, et al. Tissue invasion by Entamoeba histolytica: Evidence of genetic selection and/or DNA reorganization events in organ tropism. PLoS Negl Trop Dis 2008; 2 (6): e219.
34. Olivos-García A, Saavedra E, Ramos-Martínez E, Nequiz M, Pérez-Tamayo R. Molecular nature of virulence in Entamoeba histolytica. Infect Genet Evol 2009; 9: 1033-7.
35. Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev 2007; 20 (3): 511-32.
36. Salles JM, Moraes LA, Salles MC. Hepatic amebiasis. Braz J Infect Dis 2003; 7 (2): 96-110.
37. Chacín-Bonilla L. Diagnóstico microscópico de amibiasis: Método obsoleto pero necesario en el mundo en desarrollo. Invest Clin 2011; 52 (4): 291-4.
38. Botero DA, Restrepo M. Parasitosis humana. Editorial Presencia Ltda, Bogotá, Colombia. 1992; 418 pp.
39. Petri WA Jr. Therapy of intestinal protozoa. Trends Parasitol 2003; 19 (11): 523-6.
40. Bobbi S, Pritt MD, Clark G. Amebiasis. Mayo Clin Proc 2008; 83 (10): 1154-60.
41. Knight R. The chemotherapy of amoebiasis. J Antimicrob Chemother 1980; 6: 577-593.
42. Hayat F, Salahuddin A, Zargan J, Azam A. Synthesis, characterization, antiamoebic activity and cyto toxicity of novel 2-(quinolin-8-yloxy) acetohydrazones and their cyclized products (1,2,3-thiadiazole and 1,2,3-selenadiazole derivatives). Eur J Med Chem 2010; 45: 6127-34.
43. Escobedo AA, Cimerman S. Giardiasis: a pharmacotherapy review. Expert Opin Pharmacother 2007; 8 (12): 1885-902.
44. Fujishima T, Nishise S, Ichihara M, Kobayashi S, Takeuchi T. Difficulties in the treatment of intestinal amoebiasis in mentally disabled individuals at a rehabilitation institution for the intellectually impaired in Japan. Chemotherapy 2010; 56: 348-52.
45. Ali V, Nozaki T. Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "Amitochondriate" protozoan parasites. Clin Microbiol Rev 2007; 20 (1): 164-87.
46. Gilles H, Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol 2002; 18 (3): 95-7.
47. Carrero JC, Contreras-Rojas A, Sánchez-Hernández B, Petrosyan P, Bobes RJ, Ortíz-Ortíz L, et al. Protection against murine intestinal amoebiasis induced by oral immunization with the 29 kDa antigen of Entamoeba histolytica and cholera toxin. Exp Parasitol 2010; 126 (3): 359-65.
48. Guo X, Barroso L, Lyerly DM, Petri WA Jr, Houpt ER. CD4+ and CD8+ T cell-and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine. Vaccine 2011; 29: 772-7.
49. Stanley SL Jr. Vaccines for amoebiasis: Barriers and opportunities. Parasitology 2006; 133 (Suppl.): S81-6.